#VisualAbstract: Presence of regression is a favourable prognostic factor for patients with stage I and II cutaneous melanoma

byTeddy Guo

December 31, 2020

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract DIVERSITY trial: Dabigatran etexilate was non-inferior to standard of care in effectively treating acute venous thromboembolism (VTE) in children

RelatedReports

StudyGraphics

#VisualAbstract: Combination of spartalizumab plus dabrafenib and trametinib does not significantly improve survival in BRAFV600-mutated metastatic melanoma

July 27, 2022

StudyGraphics

#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma

July 12, 2022

StudyGraphics

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

April 28, 2022

StudyGraphics

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

April 14, 2022

Global estimates show one third of the population may benefit from rehabilitation services

Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men

Rosuvastatin therapy for people with HIV not associated with decreased biomarkers of inflammation and immune activation

#VisualAbstract Administering bortezomib on a weekly basis VS twice weekly basis does not significantly affect progression-free survival (PFS) or overall survival (OS) in Vrd first-line therapy for multiple myeloma (bortezomib, lenalidomide, and dexamethasone)

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

#VisualAbstract: Presence of regression is a favourable prognostic factor for patients with stage I and II cutaneous melanoma

#VisualAbstract: Combination of spartalizumab plus dabrafenib and trametinib does not significantly improve survival in BRAFV600-mutated metastatic melanoma

#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

#VisualAbstract DIVERSITY trial: Dabigatran etexilate was non-inferior to standard of care in effectively treating acute venous thromboembolism (VTE) in children

Global estimates show one third of the population may benefit from rehabilitation services

RelatedReports

#VisualAbstract: Combination of spartalizumab plus dabrafenib and trametinib does not significantly improve survival in BRAFV600-mutated metastatic melanoma

#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

Global estimates show one third of the population may benefit from rehabilitation services

Rosuvastatin therapy for people with HIV not associated with decreased biomarkers of inflammation and immune activation

#VisualAbstract Administering bortezomib on a weekly basis VS twice weekly basis does not significantly affect progression-free survival (PFS) or overall survival (OS) in Vrd first-line therapy for multiple myeloma (bortezomib, lenalidomide, and dexamethasone)

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports

#VisualAbstract: Presence of regression is a favourable prognostic factor for patients with stage I and II cutaneous melanoma

RELATED REPORTS

#VisualAbstract DIVERSITY trial: Dabigatran etexilate was non-inferior to standard of care in effectively treating acute venous thromboembolism (VTE) in children

Global estimates show one third of the population may benefit from rehabilitation services

RelatedReports

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports